IP Verse

Pharmaceutical Composition - EP2140867

The patent EP2140867 was granted to Daiichi Sankyo on Aug 16, 2023. The application was originally filed on Mar 28, 2008 under application number EP08720658A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2140867

DAIICHI SANKYO
Application Number
EP08720658A
Filing Date
Mar 28, 2008
Status
Patent Maintained As Amended
Jul 14, 2023
Publication Date
Aug 16, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 30, 2018ELKINGTON AND FIFEADMISSIBLE
HEXALMay 30, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO03000657
DESCRIPTIONWO03000680
DESCRIPTIONWO03016302
DESCRIPTIONWO2004058715
INTERNATIONAL-SEARCH-REPORTJP2001151672
INTERNATIONAL-SEARCH-REPORTJP2003073274
INTERNATIONAL-SEARCH-REPORTJP2004518710
INTERNATIONAL-SEARCH-REPORTJP2005263816
INTERNATIONAL-SEARCH-REPORTWO03000657
OPPOSITIONEP1103253
OPPOSITIONEP1270006
OPPOSITIONUS2005119486
OPPOSITIONUS5506248
OPPOSITIONWO02064124
OPPOSITIONWO2004110448
OPPOSITIONWO2005060940
SEARCHEP1103253
SEARCHEP1270006
SEARCHUS2005119486
SEARCHWO02064124
SEARCHWO2004110448

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "Aquacoat® ECD", Interphex.jp, URL: http://d.interphex.jp/en/Exhibitors/2724212/WILBUR-ELLIS-COMPANY-JAPAN-LTD/Products/1161770/AquacoatR-ECD
OPPOSITION- AULTON, M. E, Pharmaceutics: The Science of Dosage Form Design, Second Edition, Churchill Livingstone, (20020000), page 4pp, 4, 249, 296, 302, 341, 368, 442, XP055494006
OPPOSITION- "Ceolus™", Ceolus.com, URL: https://www.ceolus.com/en/ceolus_outline.html
OPPOSITION- "Ceolus™ KG Grades", Ceolus.com, URL: https://www.ceolus.com/en/ceolus_kg.html
OPPOSITION- "Ceolus™ PH Grade", Ceolus.com, URL: https://www.ceolus.com/en/ceolus_ph.html
OPPOSITION- "Ceolus™ RC grade", Ceolus.com, URL: https://www.ceolus.com/en/ceolus_rc.html
OPPOSITION- "Ceolus™ UF Grade", Ceolus.com, URL: https://www.ceolus.com/en/ceolus_uf.html
OPPOSITION- Committee for Medicinal Products for Human Use (CHMP), "Assessment report Lixiana International non-proprietary name: edoxaban", EMA/321 083/2015, (20150423), pages 1 - 138, XP055494001
OPPOSITION- Daiichi Sankyo, Inc., "A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery", ClinicalTrials.com Identifier: NCT00398216, (20061110), URL: https://clinicaltrials.gov/ct2/show/NCT00398216, XP055493997
OPPOSITION- Daiichi Sankyo, Inc., "Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement", ClinicalTrials.com Identifier: NCT00107900, (20050412), URL: https://clinicaltrials.gov/ct2/show/NCT00107900, XP055493995
OPPOSITION- "Excipients Nisso HPC Hydroxypropyl Cellulose", TECHNICAL DATA SHEET, TDS-01, Version 1.6, (20130000), URL: http://www.nissoexcipients.com/PDF/Nisso_HPC_Technical_Data_Sheet_V1.6.pdf, XP055300459
OPPOSITION- FIEDLER, Lexikon der Hilfstoffe, 5. auflage, (20020000), page 660, 661, 1084, 1085, XP055499126
OPPOSITION- McGinity et al., Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, 3rd ed., (20080000), pages 5 - 6, XP055499135
OPPOSITION- Raymond C Rowe, Paul J Sheskey and Sian C Owen, The Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press, (20060000), pages 5pp, 267, 279-282, - 337-339, 450-453, 593, 726-730, 825 -827, XP055494003
OPPOSITION- Remington: The Science and Practice of Pharmacy, 20th ed, (20000000), pages 860 - 863 , 896-897, XP055499133
OPPOSITION- Römpp Chemie Lexikon, 9th ed., (19920000), pages 2281 - 2285 , 5165, XP055499119
OPPOSITION- R. VOIGT, Pharmazeutische Technologie: für Studium und Beruf, 10. auflage, (20060000), pages 299 - 300, 305-307, XP002553701
OPPOSITION- W.A. Ritschel, A. Bauer-Brandl, Die Tablette, (20020000), page 105, XP055499124
OPPOSITION- www.clinicaltrial.gov; Identifier: NCT00398216 "A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery” Available from:https://clinicaltrials.aov/ct2/show/NCT00398216
OPPOSITION- www.clinicaltrial.gov; Identifier: NCTO0107900 "Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement” Available from:https://clinicaltrials.gov/ct2/show/NCT00107900
OPPOSITION- TURPIE ALEXANDER G G, "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", Arteriosclerosis, Thrombosis, And Vascular Biology, (20070000), vol. 27, no. 6, pages 1238 - 1247, XP002672841
OPPOSITION- S. JACOB et al., "Novel Co-Processed Excipients of Mannitol and Microcrystalline Cellulose for Preparing Fast Dissolving Tablets of Glipizide", Indian J. Pharm. Sci., (20070000), pages 633 - 639, XP008156723
SEARCH- TURPIE ALEXANDER G G, "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 27, no. 6, doi:10.1161/ATVBAHA.107.139402, ISSN 1079-5642, (20070322), pages 1238 - 1247, (20070322), XP002672841 [X] 27 * part with heading "DU-176b"; page 1243 - page 1244 * [Y] 1-5,17-26

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents